NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

New York, New York--(Newsfile Corp. - November 13, 2025) - If you suffered a loss on your Baxter International, Inc. (NYSE: BAX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=177135&wire=5&utm_campaign=8or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder ad ...

Company underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™ SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company’s Form 10-Q for the quarter ended September 30, 2025. Duri ...

WARSAW, Ind., Nov. 13, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its OrthoPediatrics Specialty Bracing (“OPSB”) portfolio with two new products launches, the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems. The company now has 31 systems within its OPSB division. Developed in collaboration with globally recognized pediatric hip ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Preferred Bank (PFBC) : This banking products and services company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.6% over the last 60 days.Weatherford International plc (WFRD) : This energy services company has seen the Zacks Consensus Estimate for its current year earnings increasing 8.6% over the last 60 days.Insulet Corporation (PODD) : This insulin delivery systems company has seen the Zacks Consens ...

Deep TMS™ becomes first and only TMS device cleared in treatment of patients aged 15 to 86 suffering from depressionBURLINGTON, Mass. and JERUSALEM, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted a label expansion for the Deep Transcranial Magnetic Stimulation (Deep TMS™) s ...

INSP INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Inspire Medical Systems, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Nov 13, 2025 5:40 AM Eastern Standard Time Share SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Inspire Medical Systems, Inc. (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period†), have until January 5, 2026 to seek ap ...

文章核心观点 - 医疗保健行业为不同风险偏好的长期投资者提供了多样化的投资机会 [1] - 对于投资期限长达40年或以上的新投资者，直觉外科和强生公司是值得重点关注的两只股票 [2] 直觉外科 - 公司旗舰产品达芬奇手术系统（包括最新的da Vinci 5）和较新的Ion腔内系统用于微创手术，驱动其盈利业务 [3] - 尽管单台手术系统投资巨大，但公司大部分收入和利润来自经常性来源，包括单次使用或寿命有限的器械和附件，第三季度该部分收入超过15亿美元 [4] - 服务合同提供了显著且可靠的经常性收入流，第三季度服务收入为3.96亿美元，系统销售额为5.9亿美元，总收入达25亿美元，同比增长23% [5] - 第三季度全球手术量同比增长约20%，其中达芬奇手术增长约19%，Ion手术增长52%；系统装机量达10,763台达芬奇系统和954台Ion系统，同比分别增长13%和30% [7] - 第三季度净利润为7.04亿美元，同比增长25% [7] - 公司在机器人手术领域是主导的市场领导者，其竞争优势来自医院的高转换成本、广泛的外科医生培训基础设施和强大的专利组合 [8] - 机器人手术应用仍有巨大市场空间，公司正拓展新的专业领域和国际市场 [9] 强生公司 - 公司属于股息之王，已连续63年增加股息，最新季度股息为每股1.30美元，增长4.8%，基于当前股价的股息收益率约为2.8% [11][12] - 创新药部门是关键的业绩增长引擎，第三季度净销售额为155.6亿美元，同比增长6.8%，增长主要由肿瘤学和免疫学药物的强劲需求驱动 [13] - 例如，Darzalex销售额增长超过20%，Tremfya销售额增长超过40% [14] - 医疗科技部门近期表现优异，第三季度销售额为84.3亿美元，同比增长6.8%，增长主要由电生理心血管产品及收购的业务（如Abiomed和Shockwave Medical）驱动 [16] - 第三季度总销售额为240亿美元，同比增长6.8%，净利润为52亿美元，较上年同期大幅增长91% [16] - 公司是美国仅有的两家获得标普全球AAA信用评级的企业之一，表明其违约风险最低，信用质量最高 [17]

13 Nov 2025 New products drive broad-based growth On track to deliver targets Trading update for the ten months ended 31 October 2025 Disclaimer For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed before, during or after the Presentation meeting. This information, which does not purport to be comprehensive, has not been verified by or on behalf of t ...

诉讼核心信息 - Rosen Law Firm提醒在2024年7月26日至2025年9月17日期间购买DexCom公司证券的投资者，重要截止日期为2025年12月29日 [2] - 投资者可能有权通过风险代理收费安排获得补偿，无需支付任何自付费用 [3] - 投资者可通过指定网站、电话或电子邮件加入针对DexCom的集体诉讼 [4][7] 诉讼指控详情 - 指控称DexCom对G6和G7连续血糖监测系统进行了未经美国食品药品监督管理局授权的重大设计变更 [6] - 上述设计变更导致G6和G7设备可靠性低于前代产品，对依赖设备获取准确血糖读数的用户构成重大健康风险 [6] - 被告对G7设备的可靠性、准确性和功能性的增强宣传存在夸大，并淡化了受篡改设备所引发问题的真实严重性和健康风险 [6] - 上述情况使公司面临监管审查和执法行动风险增加，以及重大的法律、声誉和财务损害风险 [6] 律师事务所背景 - Rosen Law Firm是一家在全球范围内代表投资者的律师事务所，专注于证券集体诉讼和股东衍生诉讼 [5] - 该律所曾达成针对中国公司的史上最大证券集体诉讼和解，并在2017年被ISS评为证券集体诉讼和解数量第一 [5] - 自2013年以来，该律所每年排名前四，为投资者追回数亿美元，其中2019年即为投资者获得超过4.38亿美元 [5]